News | Neuro Imaging | October 16, 2019

Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain

Guerbet will have exclusive distribution rights of Icometrix’s artificial intelligence medical imaging solution for neuro imaging in France, Italy and Brazil

Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain

October 16, 2019 — Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil of icobrain, their software-as-a-service (SaaS) artificial intelligence (AI)-based medical imaging solution.

Icobrain is designed to help radiologists and neurologists diagnose and monitor patients with neurological disorders. The AI software extracts clinically meaningful information from brain computed tomography (CT) or magnetic resonance imaging (MRI) scans of patients with multiple sclerosis, dementia or brain injury. Icobrain can therefore be used to automate the currently manual process of identifying, marking and quantifying volumes of brain structures identified.

Icobrain has obtained marketing authorizations in numerous countries, including the United States, Europe, Canada, Brazil, Australia, Japan and India. It is already used in more than 100 hospitals and imaging centers across the world, according to Icometrix, as well as in clinical studies from major global pharmaceutical companies.

Guerbet Chief Digital Officer François Nicolas said the agreement will allow more patients with neurological disorders to benefit from the icobrain AI technology while also expanding its own portfolio of augmented intelligence solutions beyond oncology. Icometrix CEO Wim Van Hecke added that the collaboration will allow the company to serve hospitals in France, Italy and Brazil “with the best support.” 

For more information: www.guerbet.com, www.icometrix.com

Related Content

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Carestream Health will offer insights on technology, innovative new products and research in medical imaging through a new webinar series titled Carestream Talks. #RSNA20
News | Radiology Education | October 14, 2020
October 14, 2020 — Carestrea
The use of CT and X-ray in the assessment and treatment plan for President Trump underscores the critical role that medical imaging must play in the fight against COVID-19

A COVID-19 chest CT heat map from RADlogics

News | Artificial Intelligence | October 13, 2020
October 13, 2020 — Given recent high-profile cases of...